Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2012

01-09-2012 | Original Paper

Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population

Authors: Jia-hong Chen, Hui-chan He, Fu-neng Jiang, Julia Militar, Petor-yang Ran, Guo-qiang Qin, Chao Cai, Xi-bin Chen, Jin Zhao, Zi-yao Mo, Yan-ru Chen, Jian-guo Zhu, Xingyin Liu, Wei-de Zhong

Published in: Medical Oncology | Issue 3/2012

Login to get access

Abstract

The global physiological function of specifically expressed genes of prostate cancer in Chinese patients is unclear. This study aims to determine the genome-wide expression of genes related to prostate cancer in the Chinese population. Genes that were differentially expressed in prostate cancer were identified using DNA microarray technology. Expressions were validated by using real-time PCR. The identified genes were analyzed using the ingenuity pathway analysis (IPA) to investigate the gene ontology, functional pathway and network. A total of 1,444 genes (Fold time ≥ 1.5; P ≤ 0.05) were differentially expressed in prostate primary tumor tissue compared with benign tissue. IPA revealed a unique landscape where inductions of certain pathways were involved in Cell Cycle Regulation and proliferation. Network analysis not only confirmed that protein interactions lead to the deregulation of DNA Replication, Recombination and Repair, Cellular Compromise and Cell Cycle, Genetic Disorders and Connective Tissue Disorders, but it was also observed that many of the genes regulated by Myc contributed to the modulation of lipid Metabolism and Nucleic Acid Metabolism. Both pathway and network analysis exhibited some remarkable characteristics of prostate cancer for Chinese patients, which showed profound differences from that of other non-Chinese populations. These differences may provide new insights into the molecular cascade of prostate cancer that occurs in Chinese patients.
Appendix
Available only for authorised users
Literature
1.
2.
Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur J Cancer. 1997;33:340–7.PubMedCrossRef
3.
Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol. 2005;58:673–84.PubMedCrossRef
4.
Quinn DI, Henshall SM, Sutherland LR. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858–87.PubMedCrossRef
5.
Endo T, Uzawa K, Suzuki H, Tanzawa H, Ichikawa T. Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. Int J Oncol. 2009;35:499–509.PubMed
6.
Savli H, Szendröi A, Romics I, Nagy B. Gene network and canonical pathway analysis in prostate cancer: a microarray study. Exp Mol Med. 2008;40:176–85.PubMedCrossRef
7.
Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, Knott C, Thomas K, Hoppin JA, Barker J, Coble J, Sandler DP, Blair A. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol. 2003;157(9):800–14.PubMedCrossRef
8.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.PubMedCrossRef
9.
Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286:40–8.PubMedCrossRef
10.
Fujinami K, Uemura H, Ishiguro H, Kubota Y. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med. 2002;10:173–6.PubMed
11.
12.
Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307–20.PubMedCrossRef
13.
Scott A, Wang Z. Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci Rep. 2011;31:303–7.PubMedCrossRef
14.
Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004;304:1164–6.PubMedCrossRef
15.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447:661–78.CrossRef
16.
Murabito JM, Rosenberg CL, Finger D, Kreger BE, Levy D, Splansky GL, Antman K, Hwang SJ. A genome-wide association study of breast and prostate cancer in the NHLBI’s Framingham Heart Study. BMC Med Genet. 2007;8(Suppl 1):S6.PubMedCrossRef
17.
Birkenkamp-Demtroder K, Mansilla F, Sørensen FB, Kruhøffer M, Cabezón T, Christensen LL, Aaltonen LA, Verspaget HW, Ørntoft TF. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol. 2007;1:181–95.PubMedCrossRef
18.
Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Ylstra B, Smit AB, Hoogendijk WJ. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. 2010;68(2):179–86. Epub 2010 May 14.PubMedCrossRef
19.
20.
Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000;9(1):3–28.PubMed
21.
Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, Takayama K, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Homma Y, Inoue S. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology. 2009;74:391–7.PubMedCrossRef
22.
Siemes C, Visser LE, de Jong FH, Coebergh JW, Uitterlinden AG, Hofman A, Stricker BH, van Schaik RH. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer–The Rotterdam Study. Steroids. 2010;75:1024–32.PubMedCrossRef
23.
Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008;3:e2079.PubMedCrossRef
24.
Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 2008;68:1037–45.PubMedCrossRef
25.
McDonald ER III, El-Deiry WS. Cell cycle control as a basis for cancer drug development (Review). Int J Oncol. 2000;16:871–86.PubMed
26.
Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 2001;8:1487–503.PubMed
27.
Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res. 2005;65:2872–81.PubMedCrossRef
28.
Kavitha CV, Choudhary B, Raghavan SC, Muniyappa K. Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells. Biochem Biophys Res Commun. 2010;399:575–80.PubMedCrossRef
29.
Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA. 2007;104:8438–43.PubMedCrossRef
30.
Lindsey-Boltz LA, Sancar A. Tethering DNA damage checkpoint mediator proteins TopBP1 and Claspin to DNA activates ATR phosphorylation of Chk1. J Biol Chem. 2011;286:19229–36.PubMedCrossRef
31.
Gao T, Newton AC. The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem. 2002;277:31585–92.PubMedCrossRef
32.
Kaufman L, Potla U, Coleman S, Dikiy S, Hata Y, Kurihara H, He JC, D’Agati VD, Klotman PE. Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. J Biol Chem. 2010;285:25677–85.PubMedCrossRef
33.
Chung S, Furihata M, Tamura K, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene. 2009;28:2849–59.PubMedCrossRef
34.
Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N, Fujimoto K. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin Cancer Res. 2008;14:4408–16.PubMedCrossRef
35.
Tomkova K, Tomka M, Zajac V. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma. 2008;55:177–81.PubMed
36.
Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008;103:1354–68.PubMedCrossRef
37.
Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619–24.PubMedCrossRef
38.
Kiefer J, Alexander A, Farach-Carson MC. Type I collagen-mediated changes in gene expression and function of prostate cancer cells. Cancer Treat Res. 2004;118:101–24.PubMedCrossRef
39.
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21:1156–67. Epub 2008 Jun 20.PubMedCrossRef
40.
Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007;38:564–9.PubMedCrossRef
41.
Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, Campbell RA, Xie Y, Chiu R, Berenson JR, Shi W, Chen IS, Pang S. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A. Urology. 2009;73:1119–25.PubMedCrossRef
Metadata
Title
Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population
Authors
Jia-hong Chen
Hui-chan He
Fu-neng Jiang
Julia Militar
Petor-yang Ran
Guo-qiang Qin
Chao Cai
Xi-bin Chen
Jin Zhao
Zi-yao Mo
Yan-ru Chen
Jian-guo Zhu
Xingyin Liu
Wei-de Zhong
Publication date
01-09-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0088-5

Other articles of this Issue 3/2012

Medical Oncology 3/2012 Go to the issue

Original Paper

Overexpression of AQP5 in cervical cancer: correlation with clinicopathological features and prognosis

Original Paper

Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy

Original Paper

Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2

Original Paper

miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver

Original Paper

Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma

Original Paper

Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits